Argenx gets green cue in phase 2 in primary immune thrombocytopenia
The Belgian biotech, Argenx has cleared phase 2 data on efgartigimod in primary immune thrombocytopenia (ITP). The results that they received, indicate at the effectiveness of the antibody Fc fragment in patients with the autoimmune bleeding disorder. ITP patients suffer from low platelet counts. If platelet levels plunge, then bleeding inside the brain can cause serious complications. Doctors manage the disease by using either corticosteroids or SYK inhibitor Tavalisse of Rigel Pharmaceuticals, but Argenx ruminates of safer and more broadly effective therapy. To this, Chief Medical Officer of Argenx ...
